1338P TP53 truncating and missense mutations are linked to differential response to checkpoint blockade in patients with advanced non-small cell lung cancer (NSCLC)

F Citarella,M Fiorenti,A Russo,M Russano,F Buzzacchino,B Besse,A Marinello,A Lugini,G La Cava,E Sapuppo,P Muscolino,E.G Pizzutilo,L Cristofani,P Lombardi,A Cortellini,M Aldea,S Pierri,M Filetti,F Martinelli,A Vitale

doi:10.1016/j.annonc.2024.08.1393

1338P TP53 truncating and missense mutations are linked to differential response to checkpoint blockade in patients with advanced non-small cell lung cancer (NSCLC)

F Citarella, M Fiorenti + Show 18 more

https://doi.org/10.1016/j.annonc.2024.08.1393

Copy DOI

Export

Save

Cite

Journal: Annals of Oncology

Publication Date: Sep 1, 2024

#Checkpoint Blockade In Patients #Advanced Non-small Cell Lung Cancer #Non-small Cell Lung Cancer #TP53 Missense Mutations #Missense Mutations #TP53 Missense #Truncating Mutations #Advanced Cancer #Checkpoint Blockade #Differential Response

Abstract
Full-Text
Similar Papers

Abstract

Listen

1338P TP53 truncating and missense mutations are linked to differential response to checkpoint blockade in patients with advanced non-small cell lung cancer (NSCLC)

Full Text

Published Version

Check institute access

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

1338P TP53 truncating and missense mutations are linked to differential response to checkpoint blockade in patients with advanced non-small cell lung cancer (NSCLC)